<p>香港，2026 年 6 月 4 日 -（ACN Newswire）- Everest Medicines（香港交易所代码：1952.HK）宣布已与 Travere Therapeutics, Inc.（纳斯达克代码：TVTX）签署独家许可和合作协议，以开发和商业化 civorebrutinib（也称为 EVER001），这是一种潜在的最佳口服、共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂，适用于中国以外的所有市场以及东南亚的某些国家。</p>
<p>根据协议条款，Everest 将获得 1.125 亿美元的预付款。Everest 还有资格根据指定的临床开发、监管和商业里程碑，获得高达约 10.3 亿美元的额外现金支付，涵盖多达五个适应症。Travere 还将在其许可区域的未来销售中支付分级版税，基于年度净销售阈值，版税比例从高个位数到双位数不等。许可协议将在满足惯例条件后生效，包括根据 1976 年《哈特 - 斯科特 - 罗迪诺反垄断改进法》的适用等待期的到期或终止。</p>
<p>Travere Therapeutics 是一家在纳斯达克上市的美国生物制药公司（纳斯达克代码：TVTX），专注于罕见肾小球疾病领域，特别是针对 IgA 肾病和局灶性节段性肾小管硬化症（FSGS）。该公司还在开发针对罕见遗传代谢疾病的治疗方案，如同型半胱氨酸尿症（HCU）。其核心产品 FILSPARI（sparsentan）是 FDA 批准的首个也是唯一一个用于治疗 FSGS 的药物，进一步巩固了该公司在肾脏治疗领域的领先地位。</p>
<p>Civorebrutinib 有潜力作为多种免疫介导的肾脏疾病的产品管线。作为一种研究性口服、共价可逆 BTK 抑制剂，civorebrutinib 旨在为罕见免疫介导的肾脏疾病患者提供差异化的疗效、安全性和便利性。凭借强大的临床开发能力，Everest Medicines 最近在全球多中心试验、内部研发管线验证和国际许可合作方面取得了几个关键里程碑。Civorebrutinib 在 PMN 患者的 1/2 期临床试验中已展示了概念验证。之前报告的 1/2 期数据表明，抗 PLA2R 自身抗体和蛋白尿的快速和持续减少，以及高比例的免疫学和临床缓解和稳定的肾功能，经过 52 周的随访。</p>
<p>EVER001 在多种免疫介导的肾小球疾病中具有治疗开发潜力，包括 PMN、IgA 肾病、最小变病、FSGS 和狼疮性肾炎。这些疾病共享免疫介导机制，可能导致肾小球损伤，导致蛋白尿和肾功能受损，最终可能需要透析或移植。预计 EVER001 将为全球超过 1000 万名受影响患者提供新的治疗选择。Travere 计划在 PMN、免疫介导的 FSGS 和最小变病中研究 civorebrutinib，并有潜在的额外适应症。</p>
<p>‘与 Travere 的合作汇聚了在肾脏疾病开发和商业化方面的深厚专业知识，我们期待在原发性膜性肾病、免疫介导的 FSGS 和最小变病中推进 civorebrutinib，为全球严重肾脏疾病患者提供变革性疗法，’Everest Medicines 董事会主席吴亦方先生表示。‘作为一种差异化的潜在最佳疗法，civorebrutinib 在原发性膜性肾病中已展示出令人鼓舞的疗效。凭借其高度选择性和可逆的共价作用机制，它在多个免疫介导的肾脏适应症的开发中处于良好位置。Everest 仍致力于我们的双引擎战略，即业务发展合作伙伴关系和内部研发。这一合作将加速 civorebrutinib 的全球开发和潜在商业化，扩大其在自身免疫性肾脏疾病中的临床和未来商业价值，并为患者提供更多创新治疗选择。’</p>
<p>‘Civorebrutinib 是我们罕见肾脏疾病产品组合中的战略性和互补性补充，具有成为多种免疫介导的罕见肾脏疾病最佳疗法的潜力，’Travere Therapeutics 的总裁兼首席执行官 Eric Dube 博士表示。‘生活在罕见肾脏疾病中的患者仍面临重大未满足的需求，我们相信迄今为止在 IgAN 和 FSGS 方面取得的进展只是这些社区可能性的开始。Travere 在这些疾病中帮助实现了重要的首次，我们相信我们的专业知识、基础设施和对罕见肾脏社区的深厚承诺使我们能够继续推动患者的创新。凭借在原发性膜性肾病中的概念验证数据、作为一种口服可逆 BTK 抑制剂的差异化特征，以及在免疫介导的 FSGS、最小变病等疾病中的广泛机制适用性，我们相信 civorebrutinib 有潜力显著推动罕见肾脏疾病患者的治疗范式。’</p>
<p>这次艾佛瑞斯制药与 Travere Therapeutics 的合作进一步推动了 EVER001 的全球化，反映了艾佛瑞斯制药创新药物价值的持续释放。目前，艾佛瑞斯制药已建立了一个全面的肾脏产品矩阵，包括 Nefecon、MT1013 和 EVER001，涵盖了 IgA 肾病、继发性甲状旁腺功能亢进（SHPT）以及广泛的免疫介导的肾脏疾病等适应症。通过不断深化在肾脏病学领域的战略布局，艾佛瑞斯制药正在加速其全球足迹，以通过创新疗法为更多患者提供可及且可靠的治疗解决方案。</p>
<p>来源：艾佛瑞斯制药有限公司</p>
<p>版权 © 2026 ACN Newswire。保留所有权利。</p>

云顶新耀

TVTX

<p>永峰医药（Everest Medicines）宣布与 Travere Therapeutics 达成独家许可协议，涉及 civorebrutinib，这是一种潜在的最佳 BTK 抑制剂，针对罕见的肾脏疾病。永峰将获得 1.125 亿美元的预付款以及高达 10.3 亿美元的里程碑付款，外加分级版税。该协议涵盖中国以外的开发和商业化。civorebrutinib 针对免疫介导的肾脏疾病，如 PMN、IgA 肾病和 FSGS</p>

<p>HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.</p>
<div class="lb-trans"><p>香港，2026 年 6 月 4 日 -（ACN Newswire）- Everest Medicines（香港交易所代码：1952.HK）宣布已与 Travere Therapeutics, Inc.（纳斯达克代码：TVTX）签署独家许可和合作协议，以开发和商业化 civorebrutinib（也称为 EVER001），这是一种潜在的最佳口服、共价可逆布鲁顿酪氨酸激酶（BTK）抑制剂，适用于中国以外的所有市场以及东南亚的某些国家。</p>
</div><p>Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.</p>
<div class="lb-trans"><p>根据协议条款，Everest 将获得 1.125 亿美元的预付款。Everest 还有资格根据指定的临床开发、监管和商业里程碑，获得高达约 10.3 亿美元的额外现金支付，涵盖多达五个适应症。Travere 还将在其许可区域的未来销售中支付分级版税，基于年度净销售阈值，版税比例从高个位数到双位数不等。许可协议将在满足惯例条件后生效，包括根据 1976 年《哈特 - 斯科特 - 罗迪诺反垄断改进法》的适用等待期的到期或终止。</p>
</div><p>Travere Therapeutics, is a Nasdaq-listed US biopharmaceutical company (NASDAQ: TVTX) with a focus on the field of rare glomerular diseases, particularly targeting IgA nephropathy and focal segmental glomerulosclerosis (FSGS). The company is also developing therapeutic programs for rare genetic metabolic diseases, such as homocystinuria (HCU). Its core product, FILSPARI'(sparsentan) is the first and only medicine approved by the FDA for the treatment of FSGS, further strengthening the company's leading position in the renal therapy sector.</p>
<div class="lb-trans"><p>Travere Therapeutics 是一家在纳斯达克上市的美国生物制药公司（纳斯达克代码：TVTX），专注于罕见肾小球疾病领域，特别是针对 IgA 肾病和局灶性节段性肾小管硬化症（FSGS）。该公司还在开发针对罕见遗传代谢疾病的治疗方案，如同型半胱氨酸尿症（HCU）。其核心产品 FILSPARI（sparsentan）是 FDA 批准的首个也是唯一一个用于治疗 FSGS 的药物，进一步巩固了该公司在肾脏治疗领域的领先地位。</p>
</div><p>Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. As an investigational oral, covalent reversible BTK inhibitor, civorebrutinib is designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney disease. Driven by strong clinical development capabilities, Everest Medicines has recently achieved several key milestones in global multi-center trials, in-house R&amp;D pipeline validation, and international licensing partnerships. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up.</p>
<div class="lb-trans"><p>Civorebrutinib 有潜力作为多种免疫介导的肾脏疾病的产品管线。作为一种研究性口服、共价可逆 BTK 抑制剂，civorebrutinib 旨在为罕见免疫介导的肾脏疾病患者提供差异化的疗效、安全性和便利性。凭借强大的临床开发能力，Everest Medicines 最近在全球多中心试验、内部研发管线验证和国际许可合作方面取得了几个关键里程碑。Civorebrutinib 在 PMN 患者的 1/2 期临床试验中已展示了概念验证。之前报告的 1/2 期数据表明，抗 PLA2R 自身抗体和蛋白尿的快速和持续减少，以及高比例的免疫学和临床缓解和稳定的肾功能，经过 52 周的随访。</p>
</div><p>EVER001 possesses therapeutic development potential in multiple immune-mediated glomerular diseases, including PMN, IgA nephropathy, MCD, FSGS, and lupus nephritis. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. EVER001 is expected to offer a new treatment option for more than 10 million affected patients globally. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications.</p>
<div class="lb-trans"><p>EVER001 在多种免疫介导的肾小球疾病中具有治疗开发潜力，包括 PMN、IgA 肾病、最小变病、FSGS 和狼疮性肾炎。这些疾病共享免疫介导机制，可能导致肾小球损伤，导致蛋白尿和肾功能受损，最终可能需要透析或移植。预计 EVER001 将为全球超过 1000 万名受影响患者提供新的治疗选择。Travere 计划在 PMN、免疫介导的 FSGS 和最小变病中研究 civorebrutinib，并有潜在的额外适应症。</p>
</div><p>'This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,' said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. 'As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&amp;D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.'</p>
<div class="lb-trans"><p>‘与 Travere 的合作汇聚了在肾脏疾病开发和商业化方面的深厚专业知识，我们期待在原发性膜性肾病、免疫介导的 FSGS 和最小变病中推进 civorebrutinib，为全球严重肾脏疾病患者提供变革性疗法，’Everest Medicines 董事会主席吴亦方先生表示。‘作为一种差异化的潜在最佳疗法，civorebrutinib 在原发性膜性肾病中已展示出令人鼓舞的疗效。凭借其高度选择性和可逆的共价作用机制，它在多个免疫介导的肾脏适应症的开发中处于良好位置。Everest 仍致力于我们的双引擎战略，即业务发展合作伙伴关系和内部研发。这一合作将加速 civorebrutinib 的全球开发和潜在商业化，扩大其在自身免疫性肾脏疾病中的临床和未来商业价值，并为患者提供更多创新治疗选择。’</p>
</div><p>'Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,' said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. 'Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.'</p>
<div class="lb-trans"><p>‘Civorebrutinib 是我们罕见肾脏疾病产品组合中的战略性和互补性补充，具有成为多种免疫介导的罕见肾脏疾病最佳疗法的潜力，’Travere Therapeutics 的总裁兼首席执行官 Eric Dube 博士表示。‘生活在罕见肾脏疾病中的患者仍面临重大未满足的需求，我们相信迄今为止在 IgAN 和 FSGS 方面取得的进展只是这些社区可能性的开始。Travere 在这些疾病中帮助实现了重要的首次，我们相信我们的专业知识、基础设施和对罕见肾脏社区的深厚承诺使我们能够继续推动患者的创新。凭借在原发性膜性肾病中的概念验证数据、作为一种口服可逆 BTK 抑制剂的差异化特征，以及在免疫介导的 FSGS、最小变病等疾病中的广泛机制适用性，我们相信 civorebrutinib 有潜力显著推动罕见肾脏疾病患者的治疗范式。’</p>
</div><p>This cooperation between Everest Medicines and Travere Therapeutics further propels the globalization of EVER001, reflecting the continued unlocking of the value of Everest Medicines innovative drugs. Currently, Everest Medicines has established a comprehensive renal product matrix inclding Nefecon', MT1013, and EVER001, spanning indications such as IgA nephropathy, secondary hyperparathyroidism (SHPT), and a wide range of immune-mediated kidney diseases. By continuously deepening its strategic layout in nephrology, Everest Medicines is accelerating its global footprint to provide accessible and reliable treatment solutions for more patients through innovative therapies.</p>
<div class="lb-trans"><p>这次艾佛瑞斯制药与 Travere Therapeutics 的合作进一步推动了 EVER001 的全球化，反映了艾佛瑞斯制药创新药物价值的持续释放。目前，艾佛瑞斯制药已建立了一个全面的肾脏产品矩阵，包括 Nefecon、MT1013 和 EVER001，涵盖了 IgA 肾病、继发性甲状旁腺功能亢进（SHPT）以及广泛的免疫介导的肾脏疾病等适应症。通过不断深化在肾脏病学领域的战略布局，艾佛瑞斯制药正在加速其全球足迹，以通过创新疗法为更多患者提供可及且可靠的治疗解决方案。</p>
</div><p>Source: Everest Medicines Limited</p>
<div class="lb-trans"><p>来源：艾佛瑞斯制药有限公司</p>
</div><p>Copyright 2026 ACN Newswire . All rights reserved.</p>
<div class="lb-trans"><p>版权 © 2026 ACN Newswire。保留所有权利。</p>
</div>

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

云顶新耀与 Travere Therapeutics 达成独家许可协议，针对 Civorebrutinib，这是一种可能成为同类最佳的 BTK 抑制剂，用于治疗罕见肾病，从而推动价值转换